Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.53 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.52 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.52 |
| ▸ | ITGAL | P20701 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | REN | P00797 | 1/20 | 0.51 |
| ▸ | NLN | Q9BYT8 | 2/20 | 0.50 |
| ▸ | MME | P08473 | 1/20 | 0.50 |
| ▸ | ECE1 | P42892 | 1/20 | 0.50 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29971925 | 1.00 | CYP3A4 (0.53) | CYP3A4SLC7A5ITGB2ICAM1ITGAL | |
| Hydrochloric Acid SCHEMBL20335511 | 0.99 | CYP3A4 (0.52) | CYP3A4SLC7A5ITGB2ICAM1ITGAL | |
| SCHEMBL21828646 | 0.95 | CYP3A4 (0.56) | CYP3A4SLC7A5RENNLN | |
| SCHEMBL29971719 | 0.91 | REN (0.60) | CYP3A4SLC7A5ITGB2ICAM1ITGAL | |
| SCHEMBL28133942 | 0.91 | REN (0.60) | CYP3A4SLC7A5ITGB2ICAM1ITGAL | |
| SCHEMBL21828671 | 0.88 | CYP3A4 (0.68) | CYP3A4SLC7A5ITGB2ICAM1ITGAL | |
| SCHEMBL13563455 | 0.87 | REN (0.67) | REN | |
| SCHEMBL30184773 | 0.86 | AGTR2 (0.60) | CYP3A4SLC7A5ITGB2ICAM1ITGAL | |
| SCHEMBL27826956 | 0.86 | AGTR2 (0.60) | CYP3A4SLC7A5ITGB2ICAM1ITGAL | |
| SCHEMBL29380221 | 0.86 | CYP3A4 (0.65) | CYP3A4SLC7A5ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331333-B2 | Enhancers of neurolysin activity | TEXAS TECH UNIVERSITY SYSTEM (US) | 2025-06-17 | — | — | US | disclosed |
| CN-119931966-A | BsBacD enzyme mutant, enzyme composition and preparation method of tyrosine dipeptide | 深圳瑞德林生物技术有限公司 | 2025-05-06 | — | — | CN | disclosed |
| WO-2020071258-A1 | PROTEIN GLYCATION SUPPRESSANT | 味の素株式会社 | 2020-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12331333-B2 | Enhancers of neurolysin activity | GAP43, NLN, BDNF | CYP3A4 4851/4885SLC7A5 1148/4885ITGB2 4482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.